Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant

NCT02970682 is registered in ClinicalTrials.gov with Evgen Pharma as lead sponsor.

NCT NCT02970682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02970682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
Lead sponsor
Evgen Pharma
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
March 31, 2019
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm